C. Schlichting
Impact in
- Oncology top 5%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 9
- Colorectal Cancer Treatments and Studies 7
- Cancer Treatment and Pharmacology 4
- Chemokine receptors and signaling 2
-
- Immunotherapy and Immune Responses 4
- T-cell and B-cell Immunology 3
- Atherosclerosis and Cardiovascular Diseases 2
- Co-authors
- Michael Weis (7 shared papers)Claus-Christoph Steffens (2 shared papers)Christophe Borg (2 shared papers)Dirk Arnold (2 shared papers)José María Viéitez (1 shared paper)Jaafar Bennouna (2 shared papers)Pia Österlund (3 shared papers)Richard Greil (3 shared papers)
In The Last Decade
C. Schlichting
16 papers receiving 1.2k citations
C. Schlichting's Hit Papers
Peers
Comparison fields: 5 of 70
- Oncology 731
- Hepatology 188
- Pulmonary and Respiratory Medicine 246
- Transplantation 20
- Cancer Research 109
Countries citing papers authored by C. Schlichting
This map shows the geographic impact of C. Schlichting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Schlichting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Schlichting more than expected).
Fields of papers citing papers by C. Schlichting
This network shows the impact of papers produced by C. Schlichting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Schlichting. The network helps show where C. Schlichting may publish in the future.
Co-authors
The 25 scholars most cited alongside C. Schlichting, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Hit paper breakdown → | 2012 | 865 |
| 2 | 2002 | 91 | |
| 3 | 2003 | 53 | |
| 4 | 2006 | 40 | |
| 5 | 2006 | 39 | |
| 6 | 2004 | 35 | |
| 7 | 2007 | 19 | |
| 8 | 2001 | 18 | |
| 9 | 2005 | 11 | |
| 10 | 2005 | 10 | |
| 11 | 2007 | 7 | |
| 12 | 2005 | 7 | |
| 13 | 2004 | 6 | |
| 14 | 2004 | 3 | |
| 15 | 2012 | 2 | |
| 16 | 2013 | 1 |
About C. Schlichting
C. Schlichting is a scholar working on Oncology, Immunology, Surgery, Transplantation and Immunology and Allergy, having authored 16 papers that have together received 1.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (7 papers), Immunotherapy and Immune Responses (4 papers), Cancer Treatment and Pharmacology (4 papers), T-cell and B-cell Immunology (3 papers), Chemokine receptors and signaling (2 papers), Renal Transplantation Outcomes and Treatments (2 papers), Cell Adhesion Molecules Research (2 papers) and Atherosclerosis and Cardiovascular Diseases (2 papers). The work is most often cited by research in Oncology (731 citations), Hepatology (188 citations), Pulmonary and Respiratory Medicine (246 citations), Transplantation (20 citations) and Cancer Research (109 citations). C. Schlichting has collaborated with scholars based in Germany, Spain and Finland. Frequent co-authors include Michael Weis, Claus-Christoph Steffens, Christophe Borg, Dirk Arnold, José María Viéitez, Jaafar Bennouna, Pia Österlund, Richard Greil, Eric Van Cutsem and Stefan Kubicka. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Transplantation, Regulatory Toxicology and Pharmacology and Arteriosclerosis Thrombosis and Vascular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.